Overview
Background
Dr Mollee practices as a consultant haematologist in clinical and laboratory haematology at the Princess Alexandra Hospital and is Associate Professor with the University of Queensland Medical School.
Having trained in Brisbane and Toronto, Dr Mollee has developed an international reputation studying amyloidosis and the plasma cell dyscrasias. He holds appointments with the Medical Scientific Advisory Group of Myeloma Australia, Australian Amyloidosis Network, National Blood Cancer Taskforce and is a member of the AACB Monoclonal Gammopathy Working Group and the International Kidney & Monoclonal Gammopathy Research Group. He is a past Chairman of the Australasian Leukaemia and Lymphoma Group (ALLG) and current Chair of the Australian Amyloidosis Network. He heads the Myeloma Service as well as the Queensland Amyloidosis Centre which runs one of the few clinics in Australia dedicated exclusively to the care of patients with amyloidosis.
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Qualifications
- Masters (Coursework) of Medical Science, University of Newcastle
- Royal Australasian College of Physicians, Royal Australasian College of Physicians
- Royal College of Pathologists of Australasia, Royal College of Pathologists of Australasia
Research impacts
The research of the Queensland Amyloidosis Centre aims to improved the diagnosis, monitoring and therapy of all types of amyloidosis. The Centre, in collaboration with Pathology Queensland and the Translational Research Institute, developed laser capture macrodisscution and tandem mass spectrometry analysis to accurately diagnosis the type of amyloidosis that patients have and have introuduced this assay into the clinical laboratory. Research to improve the diagnosis and monitoring of this rare disease has also assessed immunoglobulin free light chain assays, bone scintigraphy and novel radionuclide PET tracers. The Queensland Amyloidosis Centre maintains an active clinical trial program in amyloidosis therapies including both investigator-initiated and commercial studies.
Works
Search Professor Peter Mollee’s works on UQ eSpace
2002
Conference Publication
Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.
Mollee, P, Nagy, T, Saragosa, R, Turner, R, Keating, A and Crump, M (2002). Effect of gemcitabine, dexamethasone and cisplatin salvage chemotherapy (GDP) on peripheral blood stem cell (PBSC) mobilization in patients with lymphoma.. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002. WASHINGTON: AMER SOC HEMATOLOGY.
2002
Conference Publication
Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).
Mollee, P, Gupta, V, Song, K, Tsang, R, Crump, M and Keating, A (2002). Long-term outcome following high-dose therapy with etoposide, melphalan, TBI and autologous stem cell transplantation (ASCT) for acute myeloid leukemia (AML).. 44th Annual Meeting of the American-Society-of-Hematology, Philadelphia Pennsylvania, Dec 06-10, 2002.
2002
Journal Article
Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma
Song, KW, Mollee, P, Patterson, B, Brien, W and Crump, M (2002). Pure red cell aplasia due to parvovirus following treatment with CHOP and rituximab for B-cell lymphoma. British Journal of Haematology, 119 (1), 125-127. doi: 10.1046/j.1365-2141.2002.03778.x
2002
Journal Article
Progenitor cell mobilisation - Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma
Mollee, P, Pereira, D, Nagy, T, Song, K, Saragosa, R, Keating, A and Crump, M (2002). Progenitor cell mobilisation - Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplantation, 30 (5), 273-278. doi: 10.1038/sj.bmt.1703653
2002
Conference Publication
Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia
Durrant, S, Szer, J, Bradstock, K, Nivison-Smith, I and Mollee, P (2002). Allogeneic stem cell transplantation for idiopathic myelofibrosis in Australasia. 23rd Annual Scientific Meeting of the Transplantation-Society-of-Australia-and-New-Zealand, Canberra Australia, May 11-13, 2005. LONDON: NATURE PUBLISHING GROUP.
2001
Conference Publication
Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.
Keating, A, Filshie, R, Mollee, P and Wang, XH (2001). Prolonged engraftment and transgene expression of genetically modified autologous bone marrow stromal (mesenchymal) cells after infusion post autotransplant: A platform for cell and gene therapy.. WASHINGTON: AMER SOC HEMATOLOGY.
2001
Journal Article
Single institution outcomes of treatment of severe aplastic anaemia
Mollee, P., Woodward, N., Durrant, S., Lockwood, L., Gillett, E. A., Morton, J. and Rowell, J. (2001). Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal, 31 (6), 337-342. doi: 10.1046/j.1445-5994.2001.00078.x
2001
Journal Article
Single institution outcomes of treatment of severe aplastic anaemia
Mollee, P., Woodward, N., Durrant, S., Lockwood, L., Gillett, E. A., Morton, J. and Rowell, J. (2001). Single institution outcomes of treatment of severe aplastic anaemia. Internal Medicine Journal, 31 (6), 337-342. doi: 10.1046/j.1445-5994.2001.00078.x
2001
Conference Publication
Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation
Irving, I, Williamson, J, Mollee, P, Morton, AJ, Sloots, T, Siebert, D and Durrant, S (2001). Low dose valaciclovir for the prevention of CMV disease post allogeneic bone marrow transplantation. BASINGSTOKE: NATURE PUBLISHING GROUP.
2001
Conference Publication
Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.
Durrant, S., Irving, I., Mollee, P., Morton, A. J., Webb, M. and Macfarlane, D. (2001). Phase I/II study of Sm-153 lexidronam, limb irradiation and stem cell transplantation for the treatment of multiple myeloma.. 27th Annual Meeting of the European Group for Blood and Marrow Transplantation, London, United Kingdom: Nature Publishing Group.
2000
Conference Publication
Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GVHD.
Mollee, P, Morton, J, Irving, I and Durrant, S (2000). Combination therapy with antithymocyte globulin (ATG) and tacrolimus for patients with steroid refractory GVHD..
2000
Conference Publication
A Phase II study of Interferon alpha and intermittent oral Cytarabine in the treatment of newly diagnosed Chronic Myeloid Leukaemia.
Mollee, P., Taylor, K., Arthur, C., Wright, S., Rodwell, R. and Taylor, D. (2000). A Phase II study of Interferon alpha and intermittent oral Cytarabine in the treatment of newly diagnosed Chronic Myeloid Leukaemia.. Perth, July 2000. Sydney: Haematology Society of Australia and New Zealand.
2000
Conference Publication
A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML)
Mollee, P., Taylor, K., Arthur, C., Wright, S. and Morton, J. (2000). A phase II study of interferon alpha (IFN) and intermittent oral cytarabine (YNK01) in the treatment of newly diagnosed chronic myeloid leukemia (CML). 2nd Annual Scientific Meeting of the Haematology Society of Australia and New Zealand, Perth, WA, 25-28 July 2000. Washington, D.C.: American Society of Hematology.
1999
Journal Article
Long-term molecular remission in promyelocytic transformation of myeloproliferative disease
Mollee, P. N., Taylor, K. M., Williams, B., Taylor, D. and Rodwell, R. (1999). Long-term molecular remission in promyelocytic transformation of myeloproliferative disease. Leukemia, 13 (4), 648-650. doi: 10.1038/sj.leu.2401358
1999
Journal Article
Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor
Morton, J, Mollee, P, Taylor, K, Grigg, A, Durrant, S, Moore, D, Rodwell, R, Eliadis, P, Hutchins, C, Williams, B, Seeley, G, Wright, S, Kelly, C, Rentoul, A, Iland, H, Atkinson, K, Januszewicz, H, Bunce, I, Bashford, J, Stewart, C and Taylor, D (1999). Safe mobilization of normal progenitors in advanced chronic myeloid leukemia with intensive chemotherapy and granulocyte-colony stimulating factor. Leukemia Research, 23 (2), 177-183. doi: 10.1016/S0145-2126(98)00143-X
1997
Journal Article
Promyelocytic transformation of polycythaemia vera (PV)
Mollee, P. N., Taylor, K. M. and Williams, B. (1997). Promyelocytic transformation of polycythaemia vera (PV). Australian and New Zealand journal of medicine, 27 (6), 709-710. doi: 10.1111/j.1445-5994.1997.tb01007.x
Supervision
Availability
- Associate Professor Peter Mollee is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Master Philosophy
Novel Radionuclide Tracers for Imaging in Amyloidosis
Principal Advisor
Other advisors: Associate Professor Colm Keane
-
Doctor Philosophy
Addressing frailty in older people with haematological malignancies
Associate Advisor
Other advisors: Associate Professor Emily Gordon, Dr Natasha Reid, Professor Ruth Hubbard
Media
Enquiries
For media enquiries about Associate Professor Peter Mollee's areas of expertise, story ideas and help finding experts, contact our Media team: